ArticleApplied biochemistry and biotechnology2025
USP7 Stabilizes USF1 to Aggravate ox-LDL-Induced Endothelial Injury Through the MYD88/NF-κB Pathway in Atherosclerosis.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deubiquitinases as Regulators and Therapeutic Targets in Vascular Diseases.International journal of molecular sciences · 2026Review
- USP7 Drives Atherosclerosis by Promoting Ferroptosis in Vascular Endothelial Cells via the KIAA1429/NEAT1/CTCF Axis.Biological procedures online · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is a complex disease that involves the accumulation of lipids in the arterial wall, leading to vessel narrowing and increased risk of heart disease. Upstream stimulatory factor 1 (USF1) is an important regulatory factor that plays an important role in disease progression. Understanding the role and mechanism of USF1 in AS is crucial for unraveling the molecular underpinnings of this condition. Oxidized low-density lipoprotein (Ox-LDL) was used to stimulate human umbilical vein endothelial cells (HUVECs) to induce an AS-like cellular injury. Protein expression was evaluated using western blotting, while mRNA expression was assessed via quantitative real-time polymerase chain reaction. Cell viability and proliferation were analyzed using the cell counting kit-8 and 5-ethynyl-2'-deoxyuridine assays, respectively. Cell apoptosis was examined through flow cytometry. Angiogenic capacity was assessed by tube formation assay in human umbilical vein endothelial cells (HUVECs). Enzyme-linked immunosorbent assays were conducted to measure IL-6 and TNF-α levels, and MDA levels were determined using a lipid peroxidation MDA assay kit. SOD activity was measured using an SOD activity assay kit. Co-immunoprecipitation assay was performed to investigate the association between ubiquitin-specific peptidase 7 (USP7) and USF1, while dual-luciferase reporter assay and chromatin immunoprecipitation assay were conducted to identify the association between USF1 and myeloid differentiation primary response 88 (MYD88). USF1 expression was upregulated in AS patients when compared with healthy volunteers. Knockdown of USF1 protected HUVECs from injury induced by ox-LDL. USP7 was found to stabilize USF1 protein expression by deubiquitination, and its knockdown mitigated ox-LDL-induced HUVEC injury by reducing USF1 protein expression. USF1 was shown to transcriptionally activate MYD88 in HUVECs, and silencing of USF1 protected HUVECs from ox-LDL-induced injury by inhibiting MYD88 expression. Furthermore, USF1 knockdown inactivated the NF-κB pathway by suppressing MYD88 expression. USP7-dependent stabilization of USF1 exacerbated ox-LDL-induced injury in HUVECs by activating the MYD88/NF-κB pathway. These findings underscore the importance of the USP7-USF1-MYD88 axis in AS and suggest potential therapeutic targets for diseases related to AS.
Indexed as
Identifiers
40679551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.